Chokecherry Bark

Chokecherry bark (Prunus virginiana) contains bioactive phenolic compounds—including catechin, epicatechin, p-coumaric acid, and the cyanogenic glycoside prunasin—that exert antioxidant, antimicrobial, and expectorant effects by scavenging reactive oxygen species, chelating pro-oxidant metal ions, and modulating mucous membrane secretion. While no controlled human clinical trials have been published to date, the bark's longstanding use in Indigenous North American and early American botanical medicine for respiratory and digestive complaints is supported by phytochemical analyses confirming the presence of these pharmacologically active constituents.

Origin & History

Chokecherry Bark (Prunus virginiana) is harvested from a deciduous tree native to temperate woodlands and riverbanks across North America, particularly Canada and the United States. This botanical is valued in functional nutrition for its unique phytochemical composition, supporting respiratory, digestive, and nervous system health.

Historical & Cultural Context

Chokecherry Bark has a rich history in Native American traditional medicine, where it was revered for its efficacy in treating lung and digestive ailments. It was also considered a sacred herb for calming the nervous system and fostering resilience, reflecting its deep cultural significance.

Health Benefits

- Supports respiratory health by acting as an expectorant and soothing irritated mucous membranes.
- Aids digestion by modulating gut motility and reducing gastrointestinal discomfort.
- Enhances immune resilience through its antimicrobial and anti-inflammatory compounds.
- Promotes relaxation and calms the nervous system via its mild sedative properties.
- Soothes inflammation throughout the body, contributing to overall comfort.
- Supports skin healing when applied topically, due to its astringent and anti-inflammatory effects.

How It Works

The bark's polyphenols—catechin, epicatechin, and p-coumaric acid—act as chain-breaking antioxidants by donating hydrogen atoms to neutralize peroxyl and hydroxyl radicals, and they chelate transition metal ions (particularly Fe²⁺ and Cu²⁺) to inhibit Fenton-reaction-driven oxidative damage. Prunasin, a cyanogenic glycoside present in the bark, is hydrolyzed by beta-glucosidase to release hydrogen cyanide in small amounts; at sub-toxic traditional doses, this is thought to exert a mild sedative effect on the respiratory center's cough reflex, acting as an antitussive. The tannins and proanthocyanidins in the bark produce astringent effects by precipitating surface proteins on mucous membranes and epithelial tissue, which reduces secretion, tightens tissue, and limits microbial adhesion. Additionally, phenolic acids such as p-coumaric acid have demonstrated inhibition of cyclooxygenase-2 (COX-2) and nuclear factor kappa B (NF-κB) signaling pathways in vitro, contributing to the bark's anti-inflammatory activity.

Scientific Research

No peer-reviewed, PubMed-indexed clinical trials specifically investigating chokecherry bark (Prunus virginiana) have been published as of 2024. Phytochemical screening studies on Prunus species have confirmed the presence of catechin, epicatechin, p-coumaric acid, and cyanogenic glycosides such as prunasin and amygdalin in bark tissues, providing a plausible biochemical basis for traditional therapeutic claims. Ethnobotanical literature extensively documents the bark's use by Indigenous North American peoples—including the Cheyenne, Blackfoot, and Jicarilla Apache—as an expectorant, digestive aid, and anti-inflammatory remedy. Future controlled human studies are needed to validate efficacy, establish dosing, and fully characterize the safety profile of chokecherry bark preparations.

Clinical Summary

Current evidence is limited to in vitro studies on related Prunus padus bark extracts, with no human clinical trials reported. Laboratory studies demonstrate antioxidant activity at 0.51 ± 0.01 μg/mL concentration and antimicrobial effects with MIC values of 125 μg/mL against Kocuria rhizophila. While emerging research supports traditional respiratory and digestive uses through documented expectorant and anti-inflammatory properties, clinical validation in human subjects remains lacking.

Nutritional Profile

- Bioactives: Prunasin (cyanogenic glycoside), Flavonoids, Polyphenols, Tannins.
- Minerals: Calcium, Potassium, Magnesium.

Preparation & Dosage

- Forms: Dried bark for teas and decoctions, powdered extract for capsules or tinctures.
- Traditional Use: Brewed into teas for respiratory and digestive issues; used in poultices for skin irritations.
- Modern Dosage: 1-2 cups of tea daily, or 300-600 mg of standardized extract daily.
- Contraindication: Due to cyanogenic glycosides, consume in recommended dosages and avoid excessive intake, especially of raw bark.

Synergy & Pairings

Role: Polyphenol/antioxidant base
Intention: Gut & Microbiome
Primary Pairings: - Turmeric (Curcuma longa)
- Ginger (Zingiber officinale)
- Ashwagandha (Withania somnifera)
- Camu Camu (Myrciaria dubia)

Safety & Interactions

Chokecherry bark contains cyanogenic glycosides (prunasin and amygdalin) that release hydrogen cyanide upon enzymatic hydrolysis; excessive consumption can cause cyanide toxicity symptoms including headache, dizziness, nausea, convulsions, and in severe cases respiratory failure and death. The bark should be avoided during pregnancy and breastfeeding, and it is contraindicated in children due to their higher sensitivity to cyanide compounds. Although specific CYP450 interaction studies for Prunus virginiana bark have not been published, the phenolic content (catechin, epicatechin) is known to modulate CYP3A4 and CYP1A2 activity in related Prunus species, suggesting caution when co-administering with drugs metabolized by these enzymes, including warfarin, certain statins, and benzodiazepines. Individuals with respiratory depression, liver disease, or those taking sedative medications should consult a qualified healthcare provider before using chokecherry bark preparations.